CClinicalTrials.gg
Sign In
Not yet recruitingNCT05647811Updated Apr 13, 2026

Study of NM8074 in Adult C3 Glomerulopathy Patients

A Phase 1/2 interventional study of NM8074 in C3 Glomerulopathy, sponsored by NovelMed Therapeutics. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by NovelMed Therapeutics · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a Phase Ib, open-label, dose-escalation study designed to evaluate the safety, efficacy, and immunogenicity of NM8074 administered intravenously to patients with C3 Glomerulopathy.

Read the detailed description

The proposed study, NM8074-C3G-101, will enroll a planned number of 18 patients, with the potential to enroll more patients. There will be 3 cohorts with 6 patients each dosed at 5, 10, or 20 mg/kg depending on which cohort they are assigned to. Enrollment in the subsequent higher dose level cohort will occur after the previous cohort has been evaluated for safety.

02

Conditions studied

  • C3 Glomerulopathy
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients ≥ 18 and ≤ 65 years at the time of consent
  • Diagnosis of C3 Glomerulopathy as confirmed by C3 nephropathy in biopsy within 12 months prior to enrollment
  • Reduced serum C3 levels (defined as less than 0.85 x lower limit of the central laboratory normal range) at Screening
  • Patients with confirmed proteinuria
  • Willing and able to understand and complete informed consent procedures, including signing and dating the informed consent form (ICF), and comply with the study visit schedule
  • Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, must have a negative pregnancy test at screening and must agree to use highly effective methods of contraception during dosing and for 1 week after stopping of investigational drug
  • Males must agree to use contraceptives and refrain from donating sperm for the duration of the study
  • Patients must have documentation of previous vaccination or be willing to be vaccinated prior to dosing with NM8074. All patients will be vaccinated against Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae according to the most current Advisory Committee on Immunization Practices (ACIP) recommendations.
  • Estimated glomerular filtration (eGFR) rate of ≤ 60 ml/min but ≥ 20 ml/min

Exclusion criteria

Exclusion Criteria:

  • Use of other investigational drugs at the time of enrollment
  • Patients with other renal diseases that would interfere with interpretation of the study
  • Estimated glomerular filtration rate of ≤ 20 mL/min/1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) at Screening
  • Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 times the upper limit of normal (xULN)
  • Has a known history of meningococcal disease or N. meningitidis
  • Currently active systemic infection or suspicion of active bacterial, viral, or fungal infection that requires antibiotic, antifungal, antiparasitic, or antiviral mediations
  • Temperature > 38°C for more than two weeks prior to screening
  • History of renal organ transplantation
  • Pregnant, planning to become pregnant, or nursing female subjects
  • C3G patients currently under complement blocker treatments
  • Participation in any experimental small molecule or non-antibody therapy within 60 days prior to dosing on Day 1 (participation in observational studies and/or registry studies is permitted)
04

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    6 subjects will receive NM8074 at 5 mg/kg weekly.

    Drug: NM8074

  • Experimental
    Cohort 2

    6 subjects will receive NM8074 at 10 mg/kg every 2 weeks.

    Drug: NM8074

  • Experimental
    Cohort 3

    6 subjects will receive NM8074 at 20 mg/kg every 2 weeks.

    Drug: NM8074

Interventions

  • DrugNM8074

    NM8074 will be administered as an intravenous infusion. Multiple dosing duration will range from 5 to 9 weeks.

05

What researchers measure

Primary outcomes

  1. Monitoring for incidence of Adverse Events (AEs)/Serious Adverse Events (SAEs)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  2. Change from Baseline or Percent Change from Baseline in Urine Protein to Creatine Concentration Ratio (UPCR)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  3. Change from Baseline or Percent Change from Baseline in Urine Albumin to Creatinine Concentration Ratio (UACR)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  4. Ratio to Baseline of UPCR and UACR

    Derived from 24h urine collection

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  5. Change from Baseline or Percent Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Secondary outcomes

  1. Percent Change from Baseline in Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Classical Pathway (CP) of Complement Activity as Measured by Percent Change in Levels of Membrane Attack Complex (MAC)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  2. Percent Change from Baseline in Alternative Pathway (AP) of Complement Activity as Compared to Percent Change from Baseline in Classical Pathway (CP) of Complement Activity as Measured by Percent Change in Levels of Complement Component C3b

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  3. Change from Baseline or Percent Change from Baseline in Serum C3 Levels

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  4. Change from Baseline or Percent Change from Baseline in Glomerular Inflammation

    Measured by change from baseline or percent change from baseline in the C3G Histologic Index for Disease Activity - Combined C5b-9 Strata. Scores range from 0-21 where a decrease in score indicates improvement.

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  5. Change from Baseline or Percent Change from Baseline in Quality of Life (QoL) Assessed via the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale, Version 4.

    The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue with a 7-day recall period. Items are scored on a 0 - 4 response scale ranging from "Not at all" to "Very much so". All items are summed to create a single fatigue score with a range from 0 to 52 with a better quality of life indicated by a higher score.

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  6. Change from Baseline or Percent Change from Baseline in Quality of Life (QoL) Assessed via the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 Scale (QLQ- C30), Version 3.0

    All EORTC QLQ-C30 scales and single-item measures range from 0 to 100. This includes 3 symptom scales (fatigue, pain, nausea and vomiting), 5 functional scales (physical, role, cognitive, emotional, and social), single-item questions addressing symptoms like insomnia, dyspnea, loss of appetite, and others that are commonly reported by cancer patients, and the perceived financial impact of the disease. A higher score is associated with a greater quality of life for global health status.

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  7. Changes in plasma concentration of NM8074

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  8. Maximum plasma concentration (Cmax)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  9. Time corresponding to Cmax (tmax)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  10. Area under the drug concentration-time curves (AUC0-t)

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  11. Change from Baseline or Percent Change from Baseline in Levels of Complement Component C3b via Alternative Pathway (AP) of Complement Activity

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  12. Change from Baseline or Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Alternative Pathway (AP) of Complement Activity

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

Other outcomes

  1. Change from Baseline or Percent Change from Baseline in Levels of Complement Component C3b via Classical Pathway (CP) of Complement Activity.

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

  2. Change from Baseline or Percent Change from Baseline in Levels of Membrane Attack Complex (MAC) via Classical Pathway (CP) of Complement Activity.

    Time frame: Up to Study Day 50 for Cohort 1 and up to study day 84 for Cohort 2 and 3

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05647811
Lead sponsor
NovelMed Therapeutics
Responsible party
Sponsor
First posted
Dec 13, 2022
Start date
May 2027 (estimated)
Primary completion
Aug 2029 (estimated)
Completion
Jul 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

Rekha Bansal
Contact
clinicalsae@novelmed.com
216-440-2696

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

NovelMed Therapeutics

Start the discussion